Analysts Raise Price Targets for Charles River Laboratories
UBS, Jefferies, Rothschild & Co Redburn, RBC and Deutsche Bank raised their price targets after the company’s third-quarter results. UBS set a $387 target, up from $357; Jefferies, $385 from $340; Rothschild & Co Redburn, $375 from $318; RBC, $352 from $322; and Deutsche Bank, $350 from $320.
Following the release of Charles River Laboratories' third-quarter 2026 financial results on November 4, several financial institutions issued updated price targets for the company on November 5, 2026. UBS raised its price target to $387 from $357 while maintaining a Buy rating. Jefferies increased its target to $385 from $340, and Rothschild & Co Redburn adjusted its target to $375 from $318. Additionally, RBC raised its target to $352 from $322 with an Outperform rating, and Deutsche Bank moved its target to $350 from $320 while maintaining a Buy rating.
These adjustments reflect analyst reactions to the company's latest quarterly performance and updated 2026 guidance.